Enzymatic hydrolysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-09 and is reviewed periodically as new material appears.
Whey protein hydrolysate appears in foods and supplements where rapid digestion, low viscosity, or reduced intact-protein content is desired. It is distinct from whey protein isolate and concentrate, which contain largely intact proteins, though hydrolysates can be made from either. In infant formula, extensively hydrolyzed whey is used in some specialty products, while partially hydrolyzed forms appear in other formulations. Human health effects depend on the specific peptide mixture and are not uniform across all hydrolysates.
Whey protein hydrolysate is a dairy ingredient produced when whey proteins are treated with proteolytic enzymes or, less commonly, acid or heat under controlled conditions. The treatment cleaves peptide bonds and yields shorter peptide chains than those found in intact whey protein. The starting material is usually sweet whey or acid whey from cheese manufacture, concentrated by membrane filtration before hydrolysis. The resulting ingredient retains many amino acids from the original protein but differs in molecular size, solubility, and taste profile.
The parent whey proteins include beta-lactoglobulin, alpha-lactalbumin, serum albumin, immunoglobulins, and glycomacropeptide, depending on the whey source. Hydrolysis does not remove these sequences; it fragments them into peptides of varying length. The peptide distribution depends on the enzyme specificity, reaction time, temperature, pH, and enzyme-to-substrate ratio. Because the mixture is heterogeneous, a single molecular weight cannot describe the product. Instead, laboratories report a distribution, often spanning from a few hundred to several thousand daltons.
Hydrolysate powders are hygroscopic and can absorb moisture during storage, which may promote caking, browning, and loss of solubility. Cool, dry conditions and sealed packaging slow these changes, while high humidity and warm temperatures accelerate Maillard reactions between peptides and residual sugars. Liquid hydrolysates are more perishable and often require refrigeration or preservatives. Shelf-life studies usually monitor moisture, color, solubility, free amino groups, and microbial load over time. Stability depends on residual lactose, water activity, packaging barrier properties, and the initial peptide profile.
Degree of hydrolysis is commonly estimated by titrating liberated carboxyl groups, measuring soluble nitrogen in trichloroacetic acid, or using o-phthaldialdehyde assays. Molecular weight distribution is often examined by size-exclusion chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis, or mass spectrometry. These methods answer different questions: titration estimates bond cleavage, while chromatography describes peptide size ranges. Because no single reference method is universally applied, values reported by different laboratories may not be directly comparable. Method details such as calibration standards and sample preparation strongly influence results.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Whey hydrolysate; hydrolyzed whey protein | Abbreviations such as WPH appear in ingredient lists |
| Appearance | Off-white to light cream powder | Color can vary with starting whey and drying method |
| Solubility class | Highly soluble in water | Short peptides often dissolve more readily than intact whey protein |
| Typical storage temperature | 15–25 °C | Cool, dry conditions limit moisture uptake and browning reactions |
| Typical analytical method | Size-exclusion chromatography | Used to estimate molecular weight distribution of peptides |
Enzymatic hydrolysis usually uses proteases from microbial, plant, or animal sources. The enzyme choice, pH, temperature, and reaction time determine which peptide bonds are cleaved and the final peptide profile. After hydrolysis, the enzyme is inactivated by heat, and the mixture is clarified, filtered, concentrated, and spray-dried. Manufacturers may use ultrafiltration to remove larger peptides or minerals. The degree of hydrolysis, often reported as a percentage, describes the proportion of peptide bonds broken. A higher degree generally means shorter peptides, but it does not by itself define taste, allergenicity, or biological activity.
Whey protein hydrolysate appears in foods, infant formula, sports nutrition, and specialized clinical nutrition. Its production can reduce viscosity and improve heat stability compared with intact whey protein. Bitterness is common because short hydrophobic peptides can activate bitter taste receptors. The ingredient is not the same as free amino acids; it remains a mixture of peptides of different lengths. Composition varies by supplier, enzyme, and process, so two hydrolysates with the same protein content may behave differently in a formulation.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with enzymes or, less often, acid or heat to break peptide bonds. The starting material is typically sweet whey or acid whey from cheese making, first concentrated and dried into whey protein concentrate or isolate. Hydrolysis shortens long protein chains into smaller peptides, changing functional properties such as solubility, viscosity, and foam formation. The resulting powder contains peptides, residual intact protein, moisture, minerals, and variable amounts of lactose and fat depending on the starting material.
Hydrolysates are generally stable as dry powders but can absorb moisture and undergo browning during warm storage. The bitter taste of some hydrolysates arises from hydrophobic peptides exposed by cleavage, and it varies with enzyme choice and degree of hydrolysis. Reduced allergenicity is sometimes claimed, but residual IgE-binding peptides may remain, especially in partial hydrolysates. Regulatory frameworks treat extensively hydrolyzed and partially hydrolyzed products differently, and labeling rules vary by country. More research is needed on how specific peptide profiles relate to clinical outcomes.
Commercial production begins with whey protein concentrate or isolate dissolved in water. A protease is added under controlled pH and temperature, and the reaction is stopped by heat or pH adjustment once a target degree of hydrolysis is reached. Membrane filtration, often ultrafiltration or diafiltration, removes enzymes and small solutes while retaining peptides. The liquid is then concentrated and spray-dried into a powder. Each step influences peptide length, mineral content, and flavor.
In 2000, the NHTSA released a regulation making trunk releases mandatory for new cars by September of the following year due, in part, to the lobbying efforts of Janette Fennell. In 2003, the IIHS began conducting side impact crash tests. In 2004, NHTSA released new tests designed to test the rollover risk of new cars and SUVs. Only the Mazda RX-8 got a 5-star rating. Also in 2003, the National Highway Traffic Safety Administration (NHTSA) introduced a female counterpart crash test dummy of Hybrid III. This dummy was just a scaled-down version of the original Hybrid III, only representing the smallest 5% of women based on mid-1970s standards. In 2009, Citroën became the first manufacturer to feature "Snowmotion", an Intelligent Anti Skid system developed in conjunction with Bosch, which gives drivers a level of control in extreme ice or snow conditions similar to a 4x4. In 2009, NHTSA upgraded its roof-crush standard for vehicles weighing 6000 pounds or less. The new standard increased the crush load requirement from 1.5 to 3 times the vehicle's curb weight.
Coiled-coil α helices are highly stable forms in which two or more helices wrap around each other in a "supercoil" structure. Coiled coils contain a highly characteristic sequence motif known as a heptad repeat, in which the motif repeats itself every seven residues along the sequence (amino acid residues, not DNA base-pairs). The first and especially the fourth residues (known as the a and d positions) are almost always hydrophobic; the fourth residue is typically leucine – this gives rise to the name of the structural motif called a leucine zipper, which is a type of coiled-coil. These hydrophobic residues pack together in the interior of the helix bundle. In general, the fifth and seventh residues (the e and g positions) have opposing charges and form a salt bridge stabilized by electrostatic interactions. Fibrous proteins such as keratin or the "stalks" of myosin or kinesin often adopt coiled-coil structures, as do several dimerizing proteins. A pair of coiled-coils – a four-helix bundle – is a very common structural motif in proteins. For example, it occurs in human growth hormone and several varieties of cytochrome. The Rop protein, which promotes plasmid replication in bacteria, is an interesting case in which a single polypeptide forms a coiled-coil and two monomers assemble to form a four-helix bundle.
ADP-ribose is an intermediate that is produced during the metabolism of NAD+, mono- or poly-unsaturated proteins, and cyclic-ADP ribose. ADP-ribose is a protein-glycating agent, and excess levels of ADP-ribose in the cell can cause non-enzymatic ADP-ribosylation. Non-enzymatic ADP-ribosylation can inactivate protein targets that contain nucleotide-binding sites when the adenylate moiety of ADP-ribose binds to them, and it can also interfere with metabolic regulation that occurs via enzymatic ADP-ribosylation. For example, actin polymerization is inhibited by non-enzymatic ADP-ribosylation at a Cys residue. Thus, it is believed that ADPRase functions in general as a house-cleaning enzyme to eliminate potentially deleterious ADP-ribose from the cell. In the literature, the detoxifying role of ADPRase is directly supported in E. coli cells. But in mammalian cells, there is only an indirect evidence linking ADPRase to a detoxifying role, and this comes from studies of the very specific rat liver ADPRibase-I by cytotoxic agents.
On 1 December 1978, the Health and Safety Executive announced their intention to prosecute the university for breach of safety legislation. The case was heard in October 1979 at Birmingham Magistrates' Court. Although the source of infection was traced, the mode and cause of transmission was not. Evidence presented by several internationally recognised experts, including Kevin McCarthy, Allan Watt Downie and Keith R. Dumbell, showed that airborne transmission from the laboratory to the telephone room where Parker was supposedly infected was highly improbable. The experts calculated that it would require 53,700 litres (11,812 imp gal) of virus fluid to have been aspirated (meaning, in this context, removed by suction of fluid and cells through a needle) and it would take 20,000 years for one particle to travel to the telephone room at the rate the fluid was aspirated. It was additionally found that although the Shooter Inquiry noted the poor state of the duct sealing in the laboratory, this was caused after the outbreak by engineers fumigating the laboratory and ducts. The university was found not guilty of causing Parker's death.
Sampling provides one rational means of verification that a production lot conforms to the requirements of technical specifications. 100% inspection does not guarantee 100% compliance and is too time-consuming and costly. Rather than evaluating all items, a specified sample is taken, inspected or tested, and a decision is made about accepting or rejecting the entire production lot. Sampling plans have known risks: an acceptable quality limit (AQL) and a rejectable quality level, such as lot tolerance percent defective (LTDP), are part of the operating characteristic curve of the sampling plan. These are primarily statistical risks and do not necessarily imply that a defective product is intentionally being made or accepted. Plans can have a known average outgoing quality limit (AOQL). A single sampling plan for attributes is a statistical method by which the lot is accepted or rejected on the basis of one sample. Suppose that we have a lot of sizes M {\displaystyle M} ; a random sample of size N < M {\displaystyle N<M} is selected from the lot; and an acceptance number B
Sources: en.wikipedia.org
Anoop's father, who was the Minister for Food and Civil Supplies, died on 30 October 2011. Following this, Anoop was nominated by the Kerala Congress (Jacob) and UDF to contest from the Piravom assembly seat previously represented by his father. His father had lost the sitting seat in 2006 elections and recaptured it in 2011 election by a margin of 157 votes. Against Anoop Jacob, CPI(M)–led LDF once again fielded M. J. Jacob, who had won against T. M. Jacob in 2006 and lost in 2011. Since the result of Piravom by-election mattered heavily to the ruling UDF who had a slender margin of 1 seat in the Legislative assembly over LDF, the constituency witnessed intense campaigning from both sides. Election was held on 17 March 2012 and results were announced on 21 March 2012. Anoop Jacob won the by-election by a significant margin of 12,071 votes. He was sworn in as an MLA on 22 March 2012. Anoop took oath as the Minister for Food & Civil Supplies on 12 April 2012 and occupied office in the North Block of the Kerala Secretariat; both portfolio & office last held by his departed father.
The primary medical treatment of acromegaly is to use somatostatin analogues – octreotide (Sandostatin) or lanreotide (Somatuline). Somatostatin analogues are also sometimes used to shrink large tumors before surgery. Because octreotide inhibits gastrointestinal and pancreatic function, long-term use causes digestive problems such as loose stools, nausea, and gas in one-third of people. In addition, approximately 25 percent of people with acromegaly develop gallstones, which are usually asymptomatic. In some cases, octreotide treatment can cause diabetes because somatostatin and its analogues can inhibit the release of insulin. With an aggressive adenoma that is not able to be operated on, there may be a resistance to octreotide in which case a second-generation SSA, pasireotide, may be used for tumor control. However, insulin and glucose levels should be carefully monitored as pasireotide has been associated with hyperglycemia by reducing insulin secretion.
The transduction of the signal through the membrane by the receptor is not completely understood. It is known that in the inactive state, the GPCR is bound to a heterotrimeric G protein complex. Binding of an agonist to the GPCR results in a conformational change in the receptor that is transmitted to the bound Gα subunit of the heterotrimeric G protein via protein domain dynamics. The activated Gα subunit exchanges GTP in place of GDP which in turn triggers the dissociation of Gα subunit from the Gβγ dimer and from the receptor. The dissociated Gα and Gβγ subunits interact with other intracellular proteins to continue the signal transduction cascade while the freed GPCR is able to rebind to another heterotrimeric G protein to form a new complex that is ready to initiate another round of signal transduction. It is believed that a receptor molecule exists in a conformational equilibrium between active and inactive biophysical states. The binding of ligands to the receptor may shift the equilibrium toward the active receptor states. Three types of ligands exist: Agonists are ligands that shift the equilibrium in favour of active states; inverse agonists are ligands that shift the equilibrium in favour of inactive states; and neutral antagonists are ligands that do not affect the equilibrium. It is not yet known how exactly the active and inactive states differ from each other.
The Swiss company GlycArt Biotechnology developed a system using CHO cells, where the cells were engineered to overexpress an enzyme called GnTIII. The effect of this overexpression is to block the formation of fucosylated oligosaccharides on the expressed antibodies. This technology was first reported in 1999 and was the basis of GlycArt Biotechnology. Roche acquired GlycArt in 2005 in order to acquire technology to afucosylate antibodies. GlycArt Biotechnology had been founded in 2000 as a spin-out company of the Swiss Federal Institute of Technology in Zurich. The first commercial product from the GlycArt acquisition was obinutuzumab, which as Gazyva gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia. Kyowa Hakko Kirin's "Potelligent" platform uses a CHO cell line in which FUT8 has been knocked out, and which produces antibodies with little to no fucose in the Fc region. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform. The Company's technology was first reported in 2004.
Sources: en.wikipedia.org
It is made from whey, a byproduct of cheese or casein production, or from whey protein concentrate or isolate. Enzymes break the intact whey proteins into shorter peptides. The final composition depends on the starting whey and the hydrolysis conditions.
No. Whey protein isolate is a purified intact protein, while hydrolysate has been enzymatically cleaved into smaller peptides, and hydrolysate can be produced from isolate or concentrate. The two ingredients differ in molecular size, taste, and functional behavior.
Hydrolysis cleaves proteins but does not necessarily remove lactose, which is a sugar. It can reduce the size of allergenic proteins, yet residual peptides may still trigger reactions in sensitive individuals. Allergen status depends on the extent of hydrolysis and must be assessed for each product.
Peptide size is commonly estimated by size-exclusion chromatography, gel electrophoresis, or mass spectrometry. These techniques separate or identify molecules according to mass or hydrodynamic volume. Results depend on calibration and method conditions, so they are best compared within the same analytical protocol.